Connect Biopharma (CNTB) investor relations material

Introduction and agenda

• Brandon Folkes hosted a discussion with Surya P. Bhatt on rademikibart, acute COPD, and Seabreeze results.

KOL background and credentials

• Bhatt is a Professor of Medicine at the University of Alabama at Birmingham, runs an advanced COPD clinic, conducts COPD trials, and directs an AI-based lung imaging research center.

Market insights and analysis

• Asthma typically features variable, reversible airflow obstruction; COPD is more often later-onset, linked primarily to smoking, and marked by fixed or partially irreversible obstruction.

• COPD exacerbation care remains centered on steroids and antibiotics; severe events can cause lasting lung-function loss and high risk of repeat exacerbation or admission in the first 30–90 days.

• Blood eosinophils identify type 2 inflammation in the mid-20% range of COPD patients; more sensitive measures may identify up to 40%. During exacerbations, type 2 inflammation may occur in 35%–40%.

• COPD exacerbations account for nearly 75% of COPD-related costs; Bhatt cited ~$7,500 per Medicare admission, with higher costs for longer stays and readmissions.